RxDoctor Payments Data

Samit Shah

Interventional Cardiology · New Haven, CTNPI 1588939623

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Abbott accounts for 68.4% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $7,801, more than ten times the $115 reported in 2019.

$19,244in general payments, 2019–2025

Across 58 payments — averaging $331.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$13K
  • Medtronic$3K
  • Edwards Lifesciences$2K
  • Shockwave Medical, Inc$1K
  • Boston Scientific$390
  • Philips North America LLC$369
  • plus $68 from 2 others
$564,570in research payments, 2019–2025

Across 9 payments — averaging $62,730 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$540K
  • Philips North America LLC$23K
  • Shockwave Medical, Inc$2K

What the payments were for

  • Consulting fees$7,75040%
  • Speaking & faculty fees$2,87515%
  • Travel & lodging$6,74035%
  • Food & beverage$1,87910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,244 in reported general payments places this provider in the 80th percentile of 73 interventional cardiology providers in Connecticut.

See all interventional cardiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$18,288
Medicare patients
44
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Icosapent Ethyl12$1,224
Verapamil ErVerapamil Hcl31$668
Metoprolol Succinate23$402
Nitroglycerin31$299
Rosuvastatin Calcium11$159
Carvedilol16$121
Amlodipine Besylate11$11

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →